Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae [1]

Clinical Microbiology and Infection

Volumn 10, Issue 1, 2004, Pages 84-85

  Livermore, David M ^a   Brown, Derek F J ^b   Quinn, John P ^c   Carmeli, Yehuda ^d   Paterson, David L ^e   Yu, Victor L ^f  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c RUSH MEDICAL COLLEGE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; IMIPENEM; ISONIAZID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; CITROBACTER FREUNDII; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG SAFETY; ENTEROBACTER; ENTEROBACTER INFECTION; ENTEROBACTERIACEAE; GENE MUTATION; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SERRATIA;

BACTERIA (MICROORGANISMS); CITROBACTER FREUNDII; ENTEROBACTER; ENTEROBACTERIACEAE; SERRATIA;

EID: 1642504894     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00831.x     Document Type: Letter

References (15)

1. Livermore DM, Brown DFJ. Detection of β-lactamase-mediated resistance. J Antimicrob Chemother 2001; 48(Suppl 1): 59-64.
2. Sanders WE, Sanders CC. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 1988; 10: 830-838.
3. Chow JW, Fine MJ, Shlaes DM et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-590.
4. Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect 2002; 8: 823-825.
5. Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995; 15: 279-291.
6. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001; 45: 2628-2630.
7. Jacobson KL, Cohen SH, Inciardi JF et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis 1995; 21: 1107-1113.
8. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa, our worst nightmare? Clin Infect Dis 2002; 34: 634-640.
9. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-1382.
10. Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother 1996; 40: 1289-1293.
11. Neu HC. Carbapenems: special properties contributing to their activity. Am J Med 1985; 78: 33-40.
12. Koppel BS, Hauser WA, Politis C, van Duin D, Daras M. Seizures in the critically ill. the role of imipenem. Epilepsia 2001; 42: 1590-1593.
13. Bornet C, Davin-Regli A, Bosi C, Pages JM, Bollet C. Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol 2000; 38: 1048-1052.
14. Norrby SR. Carbapenems in serious infections: a risk-benefit assessment. Drug Saf 2000; 22: 191-194.
15. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162: 185-190.